ROCKVILLE, Md. – August 19, 2024 – The Association for Molecular Pathology (AMP), the premier global molecular diagnostic professional society, and world-renowned pathologist Michael Laposata, MD, PhD ...
A panelist discusses how education and cost are key challenges in ensuring comprehensive molecular testing is performed in a timely manner for patients with ovarian cancer, emphasizing the need for ...
ROCKVILLE, Md. – March 31, 2025 – The Association for Molecular Pathology, the premier global molecular diagnostic professional society, and pathologist Michael Laposata , M.D. , Ph.D., today ...
To permanently access this eBook for free, fill out the short form below. Ready to revolutionise your molecular testing for myeloid malignancies? With a constantly expanding list of biomarkers, ...
IVDR: where are we now in molecular testing? How IVDR implementation is progressing in molecular biology laboratories in different European countries IVDR, the new EU legislation for in-vitro ...
Enhanced educational initiatives for physicians Greater reliance on guidelines like NCCN, which provide flexibility in clinical application Improved reimbursement policies that incentivize ...
In the following sections, we highlight ethical concerns about early adoption of molecular diagnostic testing without solid evidence or guidelines and offer practical guidance for ethical ...
Molecular testing, including chromosomal microarray analysis, distinguishes between aggressive and indolent kidney cancer subtypes, aiding in accurate diagnosis. Accurate diagnosis is critical for ...
Endometrial cancer represents the most prevalent gynecologic malignancy in high-income regions, where its management conventionally hinges on ...
3EO becomes the first point-of-care molecular technology to be retail priced below $15 per test. 3EO adds a breakthrough business model enabling more physician practices to upgrade technology from ...
Opportunities in the North America molecular diagnostics market include rising demand due to increased chronic and infectious diseases, advances in point-of-care testing, and next-generation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results